Biohaven Pharmaceutical Holding Co Ltd
Biohaven Pharmaceutical — Investor Presentation (October 2017)
40 slides from Biohaven Pharmaceutical's investor presentation, Oct 18, 2017
Slide 1: Disclaimer
Disclaimer This presentation contains forward-looking statements, including: statements about our plans to develop and commercialize our product candidates, our planned clinical trials for our rimegepant, BHV-3500, trigriluzole, BHV-0223 and BHV-5000 development programs, the timing of the availabil
Slide 2: Company Overview
Company Overview Driving towards multiple milestones across two platforms Potential for First-in-Class and Best-in-Class Treatments CGRP Receptor Antagonist Platform for Migraine (oral or intranasal therapies) Glutamate Modulator Platform for Orphan and Other Neurologic Indications Nimble, Entrepren
Slide 3: Strong Management Team Supported by Top-Tier Investors
Strong Management Team Supported by Top-Tier Investors Biohaven’s leadership team has deep expertise in development / commercialization 4 ©2017 Biohaven Management Team Team’s Prior Professional Roles Selected Development Experience Vlad Coric, M.D., Chief Executive Officer, Director Rob Berman, M.D
Slide 4: Biohaven's Lead Development Programs
Biohaven’s Lead Development Programs Small molecule / Small molecule / NCE prodrug of Obsessive-Compulsive Disorder 4Q2017 NCE prodrug of Sublingual riluzole 1Q2018 NCE NMDA Other Neuropsychiatric Broad pipeline of late-stage product candidates with significant near-term news flow expected 5 *Extern
Slide 5: CGRP Receptor Antagonist Platform
6 ©2017 Biohaven CGRP Receptor Antagonist Platform Rimegepant BHV-3500
Slide 6: Migraine is a Debilitating Illness – Not Just a 'Bad Headache'
Migraine is a Debilitating Illness – Not Just a ‘Bad Headache’ • World’s third most prevalent illness – Approximately 36 million individuals in the US are affected by migraine – Includes more than 4 million people in the US with chronic migraine • Disease alters ability to perform normal daily activ
Slide 7: Migraine Treatment Can Be Segmented Into Two Categories
Migraine Treatment Can Be Segmented Into Two Categories ~36M Migraineurs USA(1) Acute Migraineurs Chronic Migraineurs ~32M (90%) ~4M (10%) – Small molecules: Biohaven, Allergan 8 (1) American Migraine Foundation (2) ICHD-3b International Classification of Headache Disorders Acute Treatment(2) • <15
Slide 8: Triptans: Safety & Efficacy Limitations Result in Significant Unmet Need
Triptans: Safety & Efficacy Limitations Result in Significant Unmet Need of Action We believe there is a significant unmet need for a novel migraine medication that does not increase the risk of CV liability (1) Estimate according to a recent study published in the journal Headache 9 ©2017 Biohaven
Slide 9: CGRP Receptor Antagonist: Possible Mechanism of Action in Migraine
CGRP Receptor Antagonist: Possible Mechanism of Action in Migraine 1 Inhibiting pain transmission Binding of CGRP receptor antagonists to CGRP receptors suppresses transmission of pain by inhibiting central relay of pain signals from trigeminal nerve to caudal trigeminal nucleus 3 Blocking neurogeni
Slide 10: Rimegepant: Overview
Rimegepant: Overview 11 ©2017 Biohaven (1) Marcus R, et al. (2014). Cephalalgia 34(2): 114-125 Clinical Status •Phase 2b data demonstrated that rimegepant may have the ability to address important unmet needs within migraine (1) – Statistically significant improvement relative to placebo observed in
Slide 11: Rimegepant: Comprehensive and Durable Treatment Effect Observed in Phase 2b
Rimegepant: Comprehensive and Durable Treatment Effect Observed in Phase 2b ** 40 20 Placebo Sumatriptan, 10 25 75 150 300 600 Patients (n) 203 100 71 61 86 85 111 82 ** ** ** ** ** ** Placebo Sumatriptan, 10 25 75 150 300 600 Patients (n) 203 100 71 61 86 85 111 82 Nausea Freedom Phonophobia Freedo
Slide 12: Rimegepant: Well Tolerated in Phase 1 and Phase 2b
Rimegepant: Well Tolerated in Phase 1 and Phase 2b Testing of very high doses in Phase 1 and 2b provides evidence of acceptable tolerability for 75mg dose (1) (2) (3) (4) Marcus R, et al. (2014). Cephalalgia 34(2): 114-125 Adverse events occurring in ³2% of patients in any treatment group; ordered b
Slide 13: Rimegepant: Clinical Development Plan
Rimegepant: Clinical Development Plan • FDA approval for acute treatment of migraine historically required demonstrating an effect on all four co-primary endpoints: – Pain, nausea, photophobia and phonophobia Recently, FDA has considered approval based on an effect on two co-primary endpoints: (1) H
Slide 14: Rimegepant: Value Proposition
Rimegepant: Value Proposition • Oral availability – Believed to be one of only two small molecule CGRP antagonists currently in late-stage clinical development Comprehensive treatment effect across most common migraine symptoms – 75mg dose of rimegepant showed statistically significant treatment eff
Slide 15: Rimegepant: Potential To Be The Favored Choice for Acute Treatment of Migraine
Rimegepant: Potential To Be The Favored Choice for Acute Treatment of Migraine bothersome symptom O Durable treatment effect: hour not different from placebo migraines sustained pain relief O Cumbersome route of triptans directed against circulating non-responders 16 ©2017 Biohaven Compound Rimegepa
Slide 16: BHV-3500: Third Generation CGRP Receptor Antagonist
BHV-3500: Third Generation CGRP Receptor Antagonist 17 ©2017 Biohaven Clinical Status •Toxicology program underway to support submission of an IND in 2017 Potential Benefits vs. Standard of Care •Superior chemical attributes – Highly soluble, potent antagonist at the human CGRP receptor •Multiple po
Slide 17: Glutamate Modulator Platform
18 ©2017 Biohaven Glutamate Modulator Platform Trigriluzole BHV-0223 BHV-5000
Slide 18: The Role of Glutamate – Present in 90% of All Brain Synapses
The Role of Glutamate – Present in 90% of All Brain Synapses Glutamate Regulation Excitotoxicity Normal Functioning Level of Glutamate Diseased State Healthy State MEMORY AMYOTROPHIC LATERAL SCLEROSIS SYNAPTOPLASTICITY ANXIETY DEPRESSION NEURONAL CONNECTIONS STRESS RESILIENCE MELANOMA ABNORMAL CELL
Slide 19: Glutamate Mechanisms of Action in CNS
Glutamate Mechanisms of Action in CNS Glutamate transporter modulation 1 Glutamate NMDA receptor antagonism 2 Third-party clinical trials provide basis for exploration of riluzole-related candidates, trigriluzole and BHV-0223, in multiple neurologic and neuropsychiatric disorders 20 ©2017 Biohaven B
Slide 20: Riluzole: Use and Limitations
Riluzole: Use and Limitations Riluzole is the approved for the treatment of patients with amyotrophic lateral sclerosis (ALS) and proven to extend survival at approved dose n Originally marketed by Sanofi, Rilutek® (riluzole) received FDA approval in 1995 In 2013, the FDA approved the first generic
Slide 21: Unique Properties: Third Generation Prodrug
( !u nique Properties Third Generation Prodrug Selected from > 300 Synthesized • Prodrug Candidates -•Molecular Weight 419.4 g/mol "'--• Molecular Formula C15H16F3N504S•HCL --G 0 bohaven 22 ©2017 Biohaven Qpharmoceutlcols
Slide 22: Trigriluzole
Trigriluzole • Stable in Saliva, Intestinal Fluids and Liver Microsomes No Negative Food Effect Designed to Optimize: • • • • • • Improved Absorption Enhanced Bioavailability Reduced Drug Burden Reduced First Pass Metabolism Favorable Safety Profile Once Daily Dosing Actively Absorbed by PepT1 ":---
Slide 23: Trigriluzole Active Absorption in Intestinal Tract by PepT1
Trigriluzole Active Absorption in Intestinal Tract by PepT1 PepT1 • PepT1 = Peptide Transporter 1 . . 00 b1ohaven 24 ©2017 Biohaven Qpharmoceutlcols Peptide Transporter 1 Enhances Absorption of
Slide 24: Trigriluzole: Advantages vs. Riluzole
Trigriluzole: Advantages vs. Riluzole • Improved bioavailability – Trigriluzole is a substrate for the gut transporters (PepT1), improving bioavailability of the drug • No negative food effect – Trigriluzole will not be associated with special meal restrictions – In contrast to oral riluzole tablets
Slide 25: Trigriluzole: Development Strategy
Trigriluzole: Development Strategy Alzheimer’s Disease* Alzheimer’s Disease Lead indications across an array of potential neurologic & neuropsychiatric indications 26 ©2017 Biohaven * = Third-party study / collaboration ongoing or planned (ADCS Collaboration for AD; ET Study Group Collaboration for
Slide 26: Trigriluzole in SCA: Signal-to-Noise Challenges at 8 Weeks
Trigriluzole in SCA: Signal-to-Noise Challenges at 8 Weeks • • Two double-blind(1-2), placebo-controlled academic trials with riluzole show therapeutic effects (p<0.05) Biohaven Phase 2/3 SCA trial with trigriluzole failed to separate from pbo at 8 week time point; extension phase ongoing over a 12-
Slide 27: Scale Learnings Inform SCA Analyses and Trial Considerations
Scale Learnings Inform SCA Analyses and Trial Considerations • Based upon previous literature, a 1pt change in total SARA was believed to be clinically relevant – In this trial, 2 pt change was unexpectedly observed between screening and baseline in over 1/3 patients – Limits ability to detect 1pt e
Slide 28: BHV-0223: 2nd Generation Candidate for ALS and Other Disorders
2nd BHV-0223: Generation Candidate for ALS and Other Disorders ALS 29 ©2017 Biohaven Clinical Status •Phase 1 single dose PK studies show BVH-0223 associated with less PK variability than riluzole •Plan to launch a bioequivalence study in 2017 comparing BHV-0223 to riluzole ALS Therapies •Riluzole w
Slide 29: BHV-0223: Advantages vs. Riluzole
BHV-0223: Advantages vs. Riluzole • Ease of administration – An early symptom of ALS is difficulty swallowing; makes use of riluzole tablets challenging – BHV-0223 uses fast-dissolving technology that does not require swallowing or administration of liquids More predictable pharmacokinetic performan
Slide 30: BHV-0223: Phase 1 Single Dose PK Results
BHV-0223: Phase 1 Single Dose PK Results Time Post-Dose (h) 31 ©2017 Biohaven Mean plasma riluzole concentration (pg/mL) Plasma Concentration (pg/mL) Observations •Sublingual (SL) 35mg dose of BHV-0223 vs. 50mg dose of oral Rilutek (riluzole) •BHV-0223 associated with less PK variability •Oral Rilut
Slide 31: BHV-0223: Phase 1 Single Dose PK Results (Cont'd)
BHV-0223: Phase 1 Single Dose PK Results (Cont’d) 35mg of BHV-0223 delivers similar exposures to 50mg of Rilutek 32 ©2017 Biohaven Plasma Concentration (pg/mL) Observations •Phase 1 data consistent with sublingual absorption •35mg of BHV-0223 delivered a comparable exposure profile to 50mg of Rilute
Slide 32: BHV-0223: Clinical Development Plan
BHV-0223: Clinical Development Plan • Received orphan drug designation from the FDA in December 2016 for treatment of ALS – Eligible for orphan exclusivity contingent on showing BHV-0223 is clinically superior to Rilutek or other approved riluzole compounds – Clinical superiority may be demonstrated
Slide 33: BHV-5000: A Novel Low-trapping NMDA Antagonist
BHV-5000: A Novel Low-trapping NMDA Antagonist 34 ©2017 Biohaven Clinical Status •Plan to rapidly advance BHV-5000 into trials for the treatment of breathing irregularities associated with Rett syndrome, an orphan disease •NMDA modulation has the potential for applicability across a number of CNS di
Slide 34: BHV-5000: Rationale for Use in Rett Syndrome
BHV-5000: Rationale for Use in Rett Syndrome • Symptoms emerge by 6 months and patients typically diagnosed by 18 months • Anecdotal clinical reports regarding the use of ketamine link treatment effect demonstrated in (reduction of apneic episodes) BHV-5000 has potential to positively impact Rett sy
Slide 35: BHV-5000: Clinical Development Plan
BHV-5000: Clinical Development Plan • BHV-5000 is rapidly metabolized to lanicemine and, in a Phase 1 trial, concentrations of BHV-5000 were detectable in only a few subjects who received the highest dose – Clinical program for BHV-5000 will build upon AstraZeneca’s previous development efforts for
Slide 36: Milestones
37 ©2017 Biohaven Milestones
Slide 37: Upcoming Milestones: Three Candidates in Pivotal Trials by YE 2017
Upcoming Milestones: Three Candidates in Pivotal Trials by YE 2017 • 1Q18: Phase 3 topline results • 4Q2018: Topline results from 12-month, long-term safety study Rimegepant Acute Migraine • 2017: Commence toxicology program to support IND submission in 2017 • 4Q17: Commence Phase 1 trial to assess
Slide 38: Biohaven Investment Highlights
Biohaven Investment Highlights LATE-STAGE product candidates targeting neurological and rare diseases INNOVATIVE platforms: CGRP receptor and glutamate modulation BEST-IN-CLASS potential for CGRP candidate, rimegepant, in acute migraine FIRST-IN-CLASS potential for glutamate candidate trigriluzole B
Slide 39: Biohaven Pharmaceuticals
- - 0 b7ohaven 40 ©2017 Biohaven Qphormaceuticals
Slide 40: BHVN
BHVN LISTED 40 (©2017 Biohaven
Biohaven Pharmaceutical Holding — Investor Presentation (October 2017) on 6ix